<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00201409</url>
  </required_header>
  <id_info>
    <org_study_id>258</org_study_id>
    <secondary_id>P50HL074024</secondary_id>
    <nct_id>NCT00201409</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of GM-CSF in Patients With ALI/ARDS</brief_title>
  <official_title>A Randomized Trial of GM-CSF in Patients With ALI/ARDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that administration of granulocyte-macrophage colony
      stimulating factor (GM-CSF) to patients with acute lung injury/acute respiratory distress
      syndrome (ALI/ARDS) will improve the clinical course and outcome by shortening the duration
      of mechanical ventilation for these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Respiratory failure due to ALI/ARDS remains a major health problem, despite significant
      progress in intensive care unit care and ventilator management. ALI/ARDS is characterized by
      unacceptably high mortality despite enormous expenditure of health care resources. Survivors
      face long-term consequences that may affect their quality of life. New therapies are needed
      to improve early survival and to decrease long-term sequelae of this syndrome. GM-CSF is a
      naturally occurring cytokine that is present in the normal lung, with important roles in
      pulmonary homeostasis. GM-CSF is essential for normal maturation and function of alveolar
      macrophages (resident inflammatory cells that are responsible for initial defense against
      pneumonia). Alveolar epithelial cells line the gas exchange surface of the lung. Acute lung
      injury and subsequent abnormal healing is linked to delayed repair of damage to the
      epithelium following initial injury. This can then lead to pulmonary fibrosis. GM-CSF has
      potent effects on alveolar epithelial cells, promoting proliferation and limiting epithelial
      cell death. Thus, GM-CSF has a distinctive combination of activities that make it an
      excellent candidate for a therapeutic intervention in ALI/ARDS. Preliminary studies for this
      project demonstrate that GM-CSF can protect experimental animals against acute lung injury,
      can decrease susceptibility to pneumonia, and is protective against pulmonary fibrosis
      following acute lung injury. There is extensive experience with the administration of
      recombinant human GM-CSF to human patients (this biological is approved by the FDA and has
      been well-tolerated in trials involving critically ill patients). This project is based on
      the hypothesis that administration of GM-CSF will improve clinical outcomes for patients with
      ALI/ARDS.

      DESIGN NARRATIVE:

      With the assent of the attending physician, informed consent will be obtained from the
      patient or next of kin as soon as possible after case identification. Physiologic
      measurements and specimen collection will begin at the time of entry into the study. Three
      days after the patient has met criteria for ALI/ARDS or at entry into the study (whichever is
      later), he/she will be randomized to receive recombinant human GM-CSF (250 mcg/M2) or
      placebo, administered by slow intravenous infusion once daily for 14 days.

      This study will allow entry of patients who have fulfilled criteria for ALI/ARDS for up to 7
      days. Treatment will be initiated after patients have met criteria for at least 3 days.
      Treatment with GM-CSF may prove both safe and effective within the first 1-2 days of lung
      injury. However, the present study will not address that question. It is unlikely that the
      opportunity for improved outcome will be lost by delaying therapy for up to 3 days (based on
      the proposed mechanisms by which GM-CSF might benefit this patient population). Similarly,
      the decision to treat for 14 days will allow for improved outcome in patients with
      non-resolving ARDS by reducing the incidence of ventilator-associated pneumonia and by
      decreasing pathologic fibroproliferation.

      The primary endpoint for this study will be the duration of mechanical ventilation.
      Additional important endpoints will include changes in the severity of physiologic
      derangements of respiratory gas exchange, non-respiratory organ failure, and incidence of
      ventilator-associated pneumonia. Additional assessments designed to determine the mechanism
      of benefit of GM-CSF treatment will include measures of lung epithelial cell integrity and
      measures of alveolar macrophage (lung inflammatory cell) function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free Days During Days 1-28</measure>
    <time_frame>Measured at Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygenation Index Change at Day 15 From Day 1</measure>
    <time_frame>Day 1, Day 15</time_frame>
    <description>The oxygenation index is a calculation used in intensive care medicine to measure the fraction of inspired oxygen (FiO2) and its usage within the body. It is calculated as the fraction of inspired oxygen times Mean airway pressure)/Partial pressure of oxygen in arterial blood Day 15 minus first day drug or placebo administered (Day 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Without Organ Failure</measure>
    <time_frame>Measured at Day 28</time_frame>
    <description>Non-respiratory</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered by slow intravenous infusion once daily for 14 days.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>Recombinant human GM-CSF (250 mcg/M2) will be administered by slow intravenous infusion once daily for 14 days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Acute onset of illness with:

          -  PaO2/FiO2 ratio of less than 300 (ALI) or PaO2/FiO2 ratio of less than 200 (ARDS)

          -  Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph
             (infiltrates may be patchy, diffuse, homogeneous, or asymmetric)

          -  Requirement for positive pressure ventilation via an endotracheal tube

          -  No clinical evidence of left atrial hypertension (pulmonary arterial wedge pressure
             measure up to 18 mm Hg)

          -  First three criteria must occur together within a 24-hour interval

        Exclusion criteria:

          -  Greater than 7 days elapsed following institution of mechanical ventilation

          -  Pregnancy

          -  Chronic respiratory failure as defined by any of the following: 1) FEV1 less than 20
             ml/kg of PBW; or 2) FEV1/FVC less than 50%

          -  Chronic hypercapnia or hypoxemia

          -  Hospitalization within the past 6 months for acute respiratory failure

          -  Chronic home use of oxygen or mechanical ventilation

          -  Left ventricular failure as defined by New York Heart Association (NYHA) class IV
             status

          -  Neutropenia (absolute neutrophil count less than 1000 cells/mm3)

          -  History of hematological malignancy or bone marrow transplant

          -  Entry into other intervention clinical trials

          -  Decision of the patient or attending physician to forego aggressive care

          -  Expected survival rate of less than 6 months (based solely on pre-existing medical
             problems [i.e., poorly controlled neoplasm or other end-stage disease])

          -  AIDS or known history of HIV infection

          -  Prednisone (or equivalent) therapy greater than or equal to 20 mg/day for a period of
             not less than 2 months with treatment continuing within 3 weeks prior to screening

          -  Cytotoxic therapy within 3 weeks of screening

          -  Morbid obesity defined as greater than 1 kg/c, body weight

          -  At risk for increased intracranial pressure that may result from permissive
             hypercapnia or in whom permissive hypercapnia may be otherwise contraindicated

          -  Neuromuscular disease that would potentially impact ability to wean from mechanical
             ventilation

          -  Receiving extracorporeal membrane oxygenation when meeting screening criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Paine, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Utah and University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert C. Hyzy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Paine R 3rd, Wilcoxen SE, Morris SB, Sartori C, Baleeiro CE, Matthay MA, Christensen PJ. Transgenic overexpression of granulocyte macrophage-colony stimulating factor in the lung prevents hyperoxic lung injury. Am J Pathol. 2003 Dec;163(6):2397-406.</citation>
    <PMID>14633611</PMID>
  </reference>
  <reference>
    <citation>Paine R 3rd, Morris SB, Jin H, Wilcoxen SE, Phare SM, Moore BB, Coffey MJ, Toews GB. Impaired functional activity of alveolar macrophages from GM-CSF-deficient mice. Am J Physiol Lung Cell Mol Physiol. 2001 Nov;281(5):L1210-8.</citation>
    <PMID>11597913</PMID>
  </reference>
  <reference>
    <citation>Baleeiro CE, Wilcoxen SE, Morris SB, Standiford TJ, Paine R 3rd. Sublethal hyperoxia impairs pulmonary innate immunity. J Immunol. 2003 Jul 15;171(2):955-63.</citation>
    <PMID>12847267</PMID>
  </reference>
  <reference>
    <citation>Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med. 2002 Jul 15;166(2):138-43.</citation>
    <PMID>12119223</PMID>
  </reference>
  <reference>
    <citation>Matute-Bello G, Liles WC, Radella F 2nd, Steinberg KP, Ruzinski JT, Hudson LD, Martin TR. Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome. Crit Care Med. 2000 Jan;28(1):1-7.</citation>
    <PMID>10667491</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>June 25, 2012</results_first_submitted>
  <results_first_submitted_qc>April 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 27, 2015</results_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Robert C. Hyzy, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molgramostim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GM-CSF Group</title>
          <description>Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2).</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Participants will be randomized to receive placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GM-CSF Group</title>
          <description>Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2).</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Participants will be randomized to receive placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="132"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.5" spread="15.6"/>
                    <measurement group_id="B2" value="48.3" spread="13.8"/>
                    <measurement group_id="B3" value="48.4" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ventilator-free Days During Days 1-28</title>
        <time_frame>Measured at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF Group</title>
            <description>Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants will be randomized to receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator-free Days During Days 1-28</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="10.5"/>
                    <measurement group_id="O2" value="10.7" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygenation Index Change at Day 15 From Day 1</title>
        <description>The oxygenation index is a calculation used in intensive care medicine to measure the fraction of inspired oxygen (FiO2) and its usage within the body. It is calculated as the fraction of inspired oxygen times Mean airway pressure)/Partial pressure of oxygen in arterial blood Day 15 minus first day drug or placebo administered (Day 1).</description>
        <time_frame>Day 1, Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF Group</title>
            <description>Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants will be randomized to receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygenation Index Change at Day 15 From Day 1</title>
          <description>The oxygenation index is a calculation used in intensive care medicine to measure the fraction of inspired oxygen (FiO2) and its usage within the body. It is calculated as the fraction of inspired oxygen times Mean airway pressure)/Partial pressure of oxygen in arterial blood Day 15 minus first day drug or placebo administered (Day 1).</description>
          <units>oxygenation index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="10.4"/>
                    <measurement group_id="O2" value="-4.6" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Without Organ Failure</title>
        <description>Non-respiratory</description>
        <time_frame>Measured at Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF Group</title>
            <description>Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants will be randomized to receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Without Organ Failure</title>
          <description>Non-respiratory</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="11.9"/>
                    <measurement group_id="O2" value="12.8" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GM-CSF Group</title>
          <description>Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2).</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Participants will be randomized to receive placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Miscellaneous</sub_title>
                <description>These events were not documented specifically in the records available</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sepsis or Multi-organ failure</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection SAE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary SAE</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematologic</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="64"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="64"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Miscellaneous</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Hepatic</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Hyzy</name_or_title>
      <organization>University of Michigan</organization>
      <phone>7349365201</phone>
      <email>rhyzy@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

